Massimiliano Germani
Braine L'alleud, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Two phase 1 randomised studies investigating the safety and pharmacokinetics of bepranemab in healthy participants of different ethnicities.
Journal: BMJ neurology open
Published: October 03, 2025
Safety, tolerability and biomarker results of bepranemab in participants with progressive supranuclear palsy: a randomised, multicentre, double-blind, placebo-controlled, phase 1b trial.
Journal: BMJ neurology open
Published: October 01, 2025
Brain connectivity as a new target for Alzheimer's disease therapy?
Journal: Brain : a journal of neurology
Published: May 18, 2025
Combined Assessment of Function and Survival to Demonstrate the Effect of Treatment on Progressive Supranuclear Palsy.
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: April 05, 2024
A Quantitative Clinical Pharmacology-Based Framework For Model-Informed Vaccine Development.
Journal: Journal of pharmaceutical sciences
Published: September 06, 2023
Population pharmacokinetic-pharmacodynamic analysis of givinostat.
Journal: Expert opinion on drug metabolism & toxicology
Published: June 12, 2023
Evaluation and Application of a PET Tracer in Preclinical and Phase 1 Studies to Determine the Brain Biodistribution of Minzasolmin (UCB0599).
Journal: Molecular imaging and biology
Published: April 06, 2023
Phase 1/1b Studies of UCB0599, an Oral Inhibitor of α-Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease.
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: February 11, 2022
An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models.
Journal: Science translational medicine
Published: October 05, 2021
Padsevonil randomized Phase IIa trial in treatment-resistant focal epilepsy: a translational approach.
Journal: Brain communications
Published: September 09, 2020
NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 16, 2013
Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat.
Journal: Molecular medicine (Cambridge, Mass.)
Published: February 02, 2013
Last Updated: 09/26/2026